189 related articles for article (PubMed ID: 9072885)
21. 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients.
Gejyo F; Saito A; Akizawa T; Akiba T; Sakai T; Suzuki M; Nishi S; Tsubakihara Y; Hirakata H; Bessho M;
Ther Apher Dial; 2004 Dec; 8(6):443-59. PubMed ID: 15663544
[TBL] [Abstract][Full Text] [Related]
22. [The role of iron deficiency on the development of anemia in patients on regular dialysis therapy].
Zadrazil J; Papajík T; Bachleda P; Budíková M; Novotný D; Scudla V
Vnitr Lek; 1994 Jun; 40(6):362-6. PubMed ID: 8073646
[TBL] [Abstract][Full Text] [Related]
23. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous erythropoietin in the treatment of renal anaemia.
Drinovec J; Varl J
Przegl Lek; 1992; 49(1-2):38-40. PubMed ID: 1455004
[TBL] [Abstract][Full Text] [Related]
25. The role of high-dose oral iron supplementation during erythropoietin therapy for anemia of prematurity.
Bader D; Kugelman A; Maor-Rogin N; Weinger-Abend M; Hershkowitz S; Tamir A; Lanir A; Attias D; Barak M
J Perinatol; 2001 Jun; 21(4):215-20. PubMed ID: 11533837
[TBL] [Abstract][Full Text] [Related]
26. [Study of various factors that could have an impact on the treatment with erythropoietin of hemodialysis anemia].
Fernández-Gallego J; Ramos B; Ruiz A; Contreras J; Alvarez Bustos G; López de Novales E
Nefrologia; 2000; 20(2):164-70. PubMed ID: 10853198
[TBL] [Abstract][Full Text] [Related]
27. The efficiency of fractionated parenteral iron treatment in CAPD patients.
Akcicek F; Ozkahya M; Cirit M; Ok E; Unsal A; Toz H; Celik A; Atabay G; Basci A
Adv Perit Dial; 1997; 13():109-12. PubMed ID: 9360661
[TBL] [Abstract][Full Text] [Related]
28. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
[TBL] [Abstract][Full Text] [Related]
29. Comparison of parenteral iron sucrose and ferric chloride during erythropoietin therapy of haemodialysis patients.
Wu CJ; Lin HC; Lee KF; Chuang CK; Chen YC; Chen HH
Nephrology (Carlton); 2010 Feb; 15(1):42-7. PubMed ID: 20377770
[TBL] [Abstract][Full Text] [Related]
30. [Can anemia be corrected in hemodialysis patients with thalassaemia minor? ].
Di Iorio B; Guastaferro P; Gironda A; Marano V; Morrongiello L; Cillo N; Zito B; Nigro F; Frieri A; Rubino R; Bellizzi V
G Ital Nefrol; 2002; 19(5):552-9. PubMed ID: 12439845
[TBL] [Abstract][Full Text] [Related]
31. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
32. Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin.
Arndt U; Kaltwasser JP; Gottschalk R; Hoelzer D; Möller B
Ann Hematol; 2005 Mar; 84(3):159-66. PubMed ID: 15565327
[TBL] [Abstract][Full Text] [Related]
33. [Influence of iron metabolism on the efficacy of r-HuEPO (recombinant human erythropoietin) treatment of anemia in children on hemodialysis].
Pela I; Lavoratti GC; Materassi M; Burgio G; Bartolozzi G
Pediatr Med Chir; 1991; 13(5):475-7. PubMed ID: 1788107
[TBL] [Abstract][Full Text] [Related]
34. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
Acharya VN; Sinha DK; Almeida AF; Pathare AV
J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973
[TBL] [Abstract][Full Text] [Related]
35. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
36. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis.
Rosenlöf K; Kivivuori SM; Grönhagen-Riska C; Teppo AM; Slimes MA
Clin Nephrol; 1995 Apr; 43(4):249-55. PubMed ID: 7606879
[TBL] [Abstract][Full Text] [Related]
37. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients.
Reuter SE; Faull RJ; Ranieri E; Evans AM
Nephrol Dial Transplant; 2009 Mar; 24(3):990-6. PubMed ID: 18987259
[TBL] [Abstract][Full Text] [Related]
38. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO).
Saltissi D; Sauvage D; Westhuyzen J
Clin Nephrol; 1998 Jan; 49(1):45-8. PubMed ID: 9491286
[TBL] [Abstract][Full Text] [Related]
39. [Personal experience with the use of human recombinant erythropoietin in the treatment of anemia in children with chronic renal insufficiency].
Podracká L; Sasinka M; Roland R; Böör A
Cesk Pediatr; 1992 May; 47(5):268-71. PubMed ID: 1638649
[TBL] [Abstract][Full Text] [Related]
40. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients.
Auerbach M; Winchester J; Wahab A; Richards K; McGinley M; Hall F; Anderson J; Briefel G
Am J Kidney Dis; 1998 Jan; 31(1):81-6. PubMed ID: 9428456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
